Introduction {#Sec1}
============

Nitric oxide (NO) is a signaling molecule involved in the regulation of many biological processes, such as vascular and airway tone regulation, angiogenesis, inflammatory response and immunity, nerve signal transmission, and insulin synthesis \[[@CR1]\]. Nitric oxide is produced during the two-step oxidation of [l]{.smallcaps}-arginine to [l]{.smallcaps}-citrulline, catalyzed by nitric oxide synthase (NOS). There are three isoforms of the enzyme, two of which are calcium dependent and expressed constitutively---neuronal and endothelial NOS (nNOS/NOS I and eNOS/NOS III, respectively)---and one inducible and calcium independent (iNOS/NOS II). Nitric oxide synthase activity is regulated by both negative feedback \[[@CR2], [@CR3]\] and availability of [l]{.smallcaps}-arginine \[[@CR4]\]. [l]{.smallcaps}-Arginine is a semi-essential amino acid obtained either from the diet or synthesized endogenously from L-citrulline. [l]{.smallcaps}-Citrulline, in turn, can be derived from ornithine in the catabolism of proline or glutamine and glutamate, or from [l]{.smallcaps}-arginine via arginine--citrulline pathway. [l]{.smallcaps}-Citrulline can also be obtained during the degradation of asymmetric dimethylarginine (ADMA), the process catalyzed by dimethylarginine dimethylaminohydrolase (DDAH), yielding dimethylamine (DMA) as a coproduct \[[@CR5]\]. Asymmetric dimethylarginine is constitutively synthesized during the turnover of methylated proteins. In addition to being a potential source of [l]{.smallcaps}-citrulline, ADMA acts as endogenous inhibitor of several NOS isoforms, including nNOS, and regulates [l]{.smallcaps}-arginine availability by controlling the transport of amino acid across the cell membranes \[[@CR6]--[@CR8]\]. Symmetric dimethylarginine (SDMA)---ADMA regioisomer---is considered only as a weak intermediate NOS inhibitor and is competing with [l]{.smallcaps}-arginine for transport across cell membranes \[[@CR9]\]. SDMA has been recognized as an effective marker of renal function \[[@CR10]\]. There are also growing number evidences supporting participation of SDMA in the development of inflammation and atherosclerosis.

Disturbances in NO metabolism accompanied by abnormal concentrations of its intermediates are implicated in the pathogenesis of hypertension, hypercholesterolemia, diabetes, cardiovascular and kidney diseases, schizophrenia, Alzheimer's disease, intestinal failure, and cancer \[[@CR1]\]. Therefore, [l]{.smallcaps}-arginine, [l]{.smallcaps}-citrulline, ADMA, SDMA, and DMA have gained attention as potential disease markers and/or goals of newly designed therapeutic strategies. Therefore, the concomitant determination of their exact concentration that enables the assessment of their mutual correlations is desired. Moreover, simultaneous assessment of a panel of intermediates and derivatives of NO metabolism is a time- and cost-saving approach, in which the amount of biological material, like human blood, is substantially reduced rendering the method more easily acceptable by patients. However, to the best of our knowledge, there are no methods have been reported for simultaneous measurement of [l]{.smallcaps}-arginine, [l]{.smallcaps}-citrulline, ADMA, SDMA, and DMA via liquid chromatography--mass spectrometry (LC--MS). There are only a few reported cases of DMA analysis in human biological material, including inter alia high-performance liquid chromatography (HPLC) coupled with fluorescence detection \[[@CR11]\] and gas--liquid chromatography--mass spectrometry (GLC--MS) \[[@CR12]\]. In turn, already published methods for separate quantitative analyses of ADMA and SDMA might not be easily accessible \[[@CR13]--[@CR19]\] as they require triple quadrupole mass spectrometers (operating in multiple reaction monitoring---MRM---mode). Other reported methods of ADMA and SDMA analysis without derivatization utilized hydrophilic liquid interaction chromatography (HILIC) which is suitable for small polar molecules. Some of those methods are suboptimal because they utilize trifluoroacetic acid (TFA). TFA is a known signal suppressor in electrospray ionization source (ESI), thereby decreasing method's sensitivity \[[@CR17]\]. Also, the use of HILIC methods usually involves longer column equilibration times, and HILIC column tends to show less reproducibility or durability compared with standard reversed-phase columns. In addition, the derivatization enables the analysis of molecules with *m/z* below 100, the determination of which on the QTOF mass spectrometers is problematic. Here, we present an efficient and sensitive method for the simultaneous analysis of [l]{.smallcaps}-arginine, [l]{.smallcaps}-citrulline, ADMA, SDMA, and DMA in human serum using benzoyl chloride as a derivatization reagent, analyzed by reversed-phase chromatography and by means of Xevo G2 XS Quadrupole TOF MS (Waters) with ESI ion source.

Materials and Methods {#Sec2}
=====================

Chemicals {#Sec3}
---------

Benzoyl chloride (BCl), hydrochloride salts of unlabeled dimethylamine (D0-DMA), hexadeutero-dimethylamine (D6-DMA, declared as 99 at.% 2H), [l]{.smallcaps}-arginine, SDMA, ADMA, [l]{.smallcaps}-citrulline, and sodium tetraborate were procured from Sigma-Aldrich (Poznan, Poland). Isotope-labeled [l]{.smallcaps}-arginine:HCl (D7-arginine, 98%) and asymmetric dimethylarginine (2,3,3,4,4,5,5-D7-ADMA, 98%) were obtained from Cambridge Isotope Laboratories (Tewksbury, MA, USA). Methanol, acetonitrile, water, and formic acid were acquired from Merck Millipore (Warsaw, Poland), and leucine--enkephalin was obtained from Waters (Milford, MA, USA).

Preparation of Standard Calibration Curves and Human Serum Samples {#Sec4}
------------------------------------------------------------------

Calibration standards and serum samples were prepared in the same manner. The following concentrations of calibrators, in water, were used: 5, 12.5, 25, 50, 100, 150, 200, 250 µM for [l]{.smallcaps}-arginine, 0.05, 0.13, 0.25, 0.5, 1.0, 1.5, 2, and 2.5 µM for ADMA and SDMA, and 1, 2.5, 5, 10, 20, 30, 40, and 50 µM for [l]{.smallcaps}-citrulline, and 0.14, 0.35, 0.7, 1.4, 2.8, 4.2, 5.6, 7.0 µM for DMA. The following procedure was conducted: 100 µL aliquots of calibration standards or serum, 10 µL of internal standard solution (50 µM D6-DMA, 20 µM D7-ADMA, and 100 µM D7-arginine, respectively) and 50 µL of borate buffer (0.025 M Na~2~B~4~O~7~**·**10H~2~O, 1.77 mM NaOH, pH 9.2) were placed into 2.0 mL polypropylene tubes and vortexed (1 min, 25 °C). Derivatization was conducted using 400 µL of acetonitrile (ACN) and 10 µL of 10% BCl in ACN. The solutions were incubated and vortexed (5 min, 25 °C), centrifuged (7 min, 10,000 RPM, 4 °C), and 100 µL of the clear supernatant was transferred into glass vials containing 400 µL of water.

Conditions of UPLC--ESI--MS Analysis {#Sec5}
------------------------------------

Analytical chromatography was conducted on Acquity HSS T3 column (50 × 1.0 mm, 1.75 µm) from Waters, using nanoAcquity UPLC system equipped with cooled autosampler (waters). Total run time was 10 min with total flow rate of 250 µL min^−1^ and 0.1% formic acid (FA) in water was used as a mobile phase A and 0.1% FA in methanol as mobile phase B. Sample injection volume was 2 µL. The applied gradient was as follows: 5% B for 0--0.5 min, 5--14% B for 0.5--3 min, 14--60% B for 3--4 min, 60--90% B for 4--4.5 min, 90% B for 4.5--5 min, and 90--5% B for 5--5.10 min.

MS analysis was conducted using Xevo G2 XS Quadrupole TOF MS (waters) with ESI. The spray voltage, source temperature, and the desolvation temperature were set at 0.5 kV, 120 and 450 °C, respectively. Nitrogen was used as the nebulizing and drying gas. Data were acquired by using MassLynx software (waters) for following ions (*m/z*): 279.1457, 286.1749, 307.1717, 314.2076, 280.1297, 150.0919, and 156.1113 for [l]{.smallcaps}-arginine, D7-arginine, ADMA, SDMA, D7-ADMA, [l]{.smallcaps}-citrulline, DMA, and D6-DMA, respectively (for mass spectrum see Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Mass spectra of benzamide derivatives of **a** [l]{.smallcaps}-arginine, **b** [l]{.smallcaps}-citrulline, **c** ADMA/SDMA, and **d** DMA for serum sample

Results and Discussion {#Sec6}
======================

Method Development {#Sec7}
------------------

Various analytical methods for the analysis of intermediates and derivatives of NO metabolism have been proposed. However, none of them allows for simultaneous quantitative analysis of [l]{.smallcaps}-arginine, [l]{.smallcaps}-citrulline, ADMA, SDMA, and dimethylamine. Also chromatographic separation of ADMA and SDMA without derivatization using reversed-phase column was analytically challenging. Previous approaches to chromatographic separation of ADMA and SDMA were conducted via a normal-phase chromatography \[[@CR20]\]. Recent paper by Pesek et al. \[[@CR21]\], presenting separation of ADMA and SDMA using aqueous normal-phase chromatography, demonstrated the use of in-source fragmentation mass spectrometric technique, in which, however, a complete separation of compounds was not achieved. In order to obtain partial separation, the authors have used an experimental AMPS column; however, the LC method was very long (30 min). Derivatization with benzoyl chloride used in our method, based on reversed-phase chromatography using Acquity UPLC HSS T3 column, promotes retention of analytes on the column. As a result, it enables full chromatographic separation of ADMA and SDMA in a relatively short time (up to 7 min, see Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Total ion current (TIC) and extracted ion chromatograms of benzamide derivatives of [l]{.smallcaps}-arginine, [l]{.smallcaps}-citrulline, ADMA/SDMA, and DMA for **a** calibration standard sample, **b** serum sample

Butyl derivatives, commonly used in ADMA analysis, do not allow for concomitant determination of DMA concentration \[[@CR13], [@CR22]\] and additionally require extended evaporation, which further prolongs sample preparation time. Other commonly used derivatization reagent, *ortho*-phthaldialdehyde (OPA), is mainly used in the analysis with HPLC and fluorescence detection \[[@CR23], [@CR24]\]. There have been attempts to use OPA in the analysis on a triple quadrupole mass spectrometer \[[@CR25]\]. However, the obtained quantification limits (LOQs) (3.75 µM [l]{.smallcaps}-arginine, 0.2 µM ADMA, 0.15 µM SDMA, and 1.25 µM [l]{.smallcaps}-citrulline \[[@CR25]\]) were worse. In our analytical method, we obtained better LOQs (3.2 µM [l]{.smallcaps}-arginine, 0.08 µM ADMA, 0.05 µM SDMA and 1.08 µM [l]{.smallcaps}-citrulline; see Table [1](#Tab1){ref-type="table"}). To the best of our knowledge, the very first attempt at simultaneous determination of DMA and ADMA was reported by Tsikas et al. \[[@CR12]\]. In their method, none of the procedures led to formation of suitable derivatives of ADMA. Unlike those authors, in our first attempt to quantify DMA together with other NO-associated metabolites, using 2,3,4,5,6-pentafluorobenzoyl chloride as a derivatizing reagent, we failed to obtain suitable DMA derivatives \[[@CR26]\]. Change of derivatizing agent to benzoyl chloride as well as replacing sodium carbonate with borate buffer and, consequently, a subtle pH change, improved linearity for DMA derivatives. Of note, we also noticed that a number of available pentafluorobenzoyl chloride reagents were contaminated with DMA what may contribute to the failure of previous method. Compared with the method using pentafluorobenzoyl chloride, the new method additionally allowed for shortening of extraction and derivatization time by half and for reduction in volume of deproteinizing reagent by 20%. Here, we applied ACN as the extraction solvent, which allowed for successful deproteinization and efficient extraction in a single step. The acylation process leading to a benzamide derivative was performed at 25 °C for 5 min. Neither higher temperatures nor longer reaction times visibly affected its performance. However, the efficiency of derivatization was improved by conducting the reaction under alkaline conditions, earlier reported to be optimal \[[@CR27]\]. Borate buffer was used to stabilize the pH of the samples and calibration standards. Here, we used a common internal standard, D7-ADMA, for the quantitative determination of ADMA, SDMA, and [l]{.smallcaps}-citrulline. It simplified the assay without hampering its performance, as shown by van Dyk et al. \[[@CR28]\]. Those authors demonstrated that the addition of standards for [l]{.smallcaps}-citrulline and SDMA had no positive effect on assay accuracy or precision. For the separation of samples, we used Acquity HSS T3 column (50 × 1.0 mm, 1.75 µm) with 0.22 µm membrane inline filter (waters). The development of an appropriate mobile phase gradient allowed for complete chromatographic separation of ADMA and SDMA isomers. Exemplary TIC chromatograms of benzamide derivatives of [l]{.smallcaps}-arginine, [l]{.smallcaps}-citrulline, ADMA/SDMA, and DMA standards and samples obtained using the described method are presented in Fig. [2](#Fig2){ref-type="fig"}. Mass spectrometry conditions were optimized to achieve maximum ion generation with abundance.Table 1Method validation resultsCompoundSensitivityLinearityExpected concentration (µM)Precision and accuracyWithin-run (*n* = 5)Between-run (*n* = 10)LOD (µM)LOQ (µM)Regression coefficient (*R*^2^)Slope CV (%)^a^Measured concentration (µM)Precision (CV %)Accuracy (%)Measured concentration (µM)Precision (CV %)Accuracy (%)[l]{.smallcaps}-Arginine1.73.20.9983.205\
25\
100\
2004.867 ± 0.198\
25.49 ± 0.97\
99.17 ± 2.68\
203.08 ± 4.709.14\
3.86\
1.64\
2.32102.74\
98.09\
100.83\
98.495.142 ± 0.035\
24.8 ± 01.01\
101.85 ± 3.39\
199.52 ± 5.443.63\
4.09\
3.33\
2.7397.23\
100.87\
98.19\
100.24ADMA0.030.080.9973.660.05\
0.25\
1.0\
2.50.058 ± 0.0001\
0.233 ± 0.0003\
1.012 ± 0.0004\
2.493 ± 0.00814.88\
7.53\
2.09\
3.5286.10\
107.14\
98.80\
100.300.056 ± 0.0003\
0.235 ± 0.022\
1.022 ± 0.049\
2.477 ± 0.07610.21\
9.42\
4.84\
3.0789.29\
106.47\
97.89\
100.93SDMA0.020.050.9973.330.05\
0.25\
1.0\
2.50.058 ± 0.00003\
0.239 ± 0,0002\
0.990 ± 0,002\
2.505 ± 0.0068.99\
6.39\
3.98\
3.2085.62\
104.53\
101.03\
99.810.057 ± 0.00003\
0.230 ± 0.016\
1.013 ± 0.038\
2.506 ± 0.0779.92\
7.11\
3.77\
3.0987.72\
108.79\
98.74\
99.75[l]{.smallcaps}-Citrulline0.361.080.9986.121\
10\
20\
501.036 ± 0.003\
10.00 ± 0.07\
20.304 ± 0.428\
50.019 ± 0.8295.35\
2.58\
3.22\
1.8296.53\
101.14\
98.50\
99.961.034 ± 0.093\
9.88 ± 0.044\
20.083 ± 0.617\
50.163 ± 1.479.01\
2.13\
3.07\
2.9396.72\
101.25\
99.58\
99.67DMA0.060.190.9923.890.014\
0.7\
2.8\
7.00.164 ± 0.00026\
0.698 ± 0.001\
2.71 ± 0.034\
7.19 ± 0.0169.84\
5.49\
6.80\
1.7585.32\
100.26\
103.18\
97.300.152 ± 0.00004\
0.64 ± 0.06\
2.61 ± 0.15\
7.46 ± 0.194.19\
9.74\
5.56\
5.8792.41\
109.69\
107.24\
93.81*LOD* limit of detection, *LOQ* limit of quantification, *CV* coefficient of variation^a^Variability of standard curve slopes is expressed as coefficient of variation

Method Validation {#Sec8}
-----------------

In practice, it is often difficult or impossible to obtain biological matrices devoid of measured compounds. Therefore, we prepared calibration standards in water. To demonstrate their suitability for analysis, we compared the slopes of calibration curves obtained for standards dissolved in water and serum. The obtained differences in slopes were acceptably low (\< 15%), that is, 8.29% for [l]{.smallcaps}-arginine, 5.36% for ADMA, 9.72% for SDMA, 6.25% for [l]{.smallcaps}-citrulline, and 6.57% for DMA. The established method was validated, and its assay linearity, accuracy and precision, recovery, as well as limits of detection and quantification were determined. If not otherwise stated, all data were averaged from three replicates of five separate surveys. All tests were conducted in water excluding recoveries, which were performed in serum.

### Calibration Curves and Linearity {#Sec9}

Linear regression analysis of relative areas responses vs. concentration was conducted, and regression coefficients (*R*^2^) were calculated. All calibration curves were linear with *R*^2^ \> 0.992 and coefficient of variation (CV) of calibration curves slopes at \< 6.12%. Respective data are shown in Table [1](#Tab1){ref-type="table"}.

### Accuracy, Precision, and Stability {#Sec10}

Low, medium, and high concentrations of quality control samples (respectively, QC1, QC2, and QC3) were used for determination of accuracy and precision. The results are summarized in Table [1](#Tab1){ref-type="table"}. Stability of the derivatives was tested for QC directly after derivatization procedure (0 h) and after 1 day (24 h). Samples were stored in an autosampler cooled to 6 °C. The results are depicted in Table [2](#Tab2){ref-type="table"} (presented data are average of five replicates for within-run analysis or of ten replicates for between-run analysis). All calculated CVs were below 15% and as such consistent with FDA guidelines for validation of bioanalytical methods \[[@CR29]\].Table 2Stability of compounds derivativesCompoundSample0 h concentration (µM)24 h concentration (µM)Average concentration (µM)CV (%)[l]{.smallcaps}-ArginineQC14.7254.3334.5298.03QC2105.58104.92105.381.11QC3196.67197.19196.933.01ADMAQC10.05700.05270.054814.65QC21.0880.9951.0426.99QC32.5122.4932.5031.83SDMAQC10.05930.05930.05939.57QC21.0371.0441.0412.69QC32.5462.4962.5213.81[l]{.smallcaps}-CitrullineQC11.0140.9820.9984.67QC219.88320.24920.0412.95QC350.58750.30850.5833.99DMAQC10.1540.1500.1523.65QC20.6550.6040.6349.02QC37.1527.5137.335.48*QC* quality control

### Limit of Detection and Limit of Quantification {#Sec11}

It the current study, the limit of detection (LOD) and the limit of quantification (LOQ) were defined by the standard deviation (SD) obtained for the lowest standard of the calibration curves. Three replicates (*n* = 3) of five surveys (*n* = 5) were used. The following formula was utilized: 3.3 × SD/slope for LOD and 10 × SD/slope for LOQ. The LOD and LOQ values are listed in Table [1](#Tab1){ref-type="table"}.

### Recovery {#Sec12}

Recovery rates were determined using the following formula: (response obtained for spiked serum − response of non-spiked serum)/response of calibration standard diluted in water × 100. Spiked samples were prepared using the following procedure: 25 µL of calibration standard was added to 75 µL of serum, and then derivatization reaction was performed according to the above described method. The mean recovery results are shown in Table [3](#Tab3){ref-type="table"}.Table 3Mean recovery rates of the methodSera measured concentrations mean ± SD (μM)Added concentration (μM)Spiked sera measured concentration mean ± SD (μM)Recovery (%)[l]{.smallcaps}-Arginine55.337 ± 1.93661.485\
36.741\
5.365116.03 ± 3.51\
91.19 ± 2.64\
62.42 ± 0.6998.83\
97.54\
127.82ADMA0.284 ± 0.0240.593\
0.369\
0.0650.88 ± 0.03\
0.63 ± 0.01\
0.35 ± 0.0199.41\
93.29\
96.37SDMA0.248 ± 0.0160.602\
0.369\
0.0670.79 ± 0.02\
0.56 ± 0.01\
0.31 ± 0.0190.87\
86.78\
87.00[l]{.smallcaps}-Citrulline17.617 ± 0.94512.120\
7.152\
1.25831.90 ± 2.82\
26.05 ± 3.00\
19.98 ± 2.35118.91\
118.26\
109.27DMA2.128 ± 0.1937.609\
4.517\
0.67210.05 ± 0.35\
6.85 ± 0.20\
2.98 ± 0.1103.86\
103.29\
118.99*SD* standard deviation

Method Application {#Sec13}
------------------

The established method was applied to compare the concentrations of [l]{.smallcaps}-arginine, ADMA, SDMA, [l]{.smallcaps}-citrulline, and DMA in 73 serum samples of healthy volunteers, who were previously included in studies on patients with schizophrenia \[[@CR30]--[@CR32]\]. The following data were gathered from the above group of participants: age, education, anthropometric parameters (body mass index and waist circumference), and cigarette smoking status assessed using the pack-year index and Fagerström test for nicotine dependence (FTDN) \[[@CR33]\]. These subjects had no psychiatric and known somatic health impairments. The results obtained with our method are consistent with other reports of results obtained for [l]{.smallcaps}-arginine, ADMA, SDMA, [l]{.smallcaps}-citrulline, and DMA, and are 112.84 ± 45.20, 0.38 ± 0.05, 0.33 ± 0.04, 24.54 ± 6.11, and 0.94 ± 0.39 µM, respectively. For intermediates and derivatives of NO metabolism, the reported ranges of concentrations are as follows: for [l]{.smallcaps}-arginine 129.5 ± 30 µM \[[@CR34]\], for ADMA 0.497 ± 0.063 µM \[[@CR35]\], for SDMA 0.526 ± 0.101 µM \[[@CR35]\], for [l]{.smallcaps}-citrulline 24.3 µM (median 11.6--47.3) \[[@CR36]\], and for DMA 3.3 ± 1.5 µM \[[@CR11]\]. Detailed characteristics of healthy volunteers are shown in Table [4](#Tab4){ref-type="table"}. Higher individual variability in arginine and DMA, both observed in the current study and reported elsewhere \[[@CR11]\], may reflect differences in diet between study participants, as food is an important source of both metabolites. Therefore, the possible effect of diet should be taken into account when interpreting results on arginine and DMA.Table 4General characteristics and serum levels of metabolites in healthy volunteersAge26.11 ± 3.01Sex, males (%)44 (60.3)Education, higher (%)23 (31.5)BMI, kg/m^2^22.95 ± 2.58Waist circumference (cm)78.71 ± 10.03Cigarette smoking, *n* (%)22 (30.1)FTND score1.30 ± 2.29Pack-year index1.09 ± 2.38[l]{.smallcaps}-Arginine (μM)112.84 ± 45.20Dimethylamine (μM)0.94 ± 0.39ADMA (μM)0.38 ± 0.05SDMA (μM)0.33 ± 0.04[l]{.smallcaps}-Citrulline (μM)24.54 ± 6.11[l]{.smallcaps}-Arginine: ADMA297.85 ± 126.12Data expressed as mean ± SD for continuous variables and the number of cases (%) for categorical variables*FTND* Fagerström test for nicotine dependence

Statistical Analysis {#Sec14}
--------------------

Correlations between continuous variables were evaluated using the Spearman's rank correlation test. Effects of sex on metabolic parameters were tested using the Mann--Whitney *U* test. Results were considered as statistically significant if the *p* value was \< 0.05. Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) version 20.

There were no significant correlations between general characteristics of healthy volunteers and metabolic parameters except for a significant negative correlation between serum levels of dimethylamine and age (Table [5](#Tab5){ref-type="table"}).Table 5Correlations between metabolic parameters and general characteristics of healthy volunteers[l]{.smallcaps}-Arginine[l]{.smallcaps}-CitrullineADMASDMADMA[l]{.smallcaps}-Arginine: ADMAAge*r* = − 0.052*r* = − 0.188*r* = − 0.124*r* = − 0.155*r* = − 0.274**\****r* = − 0.013BMI*r* = − 0.079*r* = 0.066*r* = − 0.077*r* = 0.055*r* = 0.168*r* = − 0.067Waist circumference*r* = − 0.065*r* = 0.073*r* = − 0.172*r* = 0.298*r* = 0.208*r* = 0.014FTND score*r* = 0.139*r* = − 0.044*r* = 0.051*r* = − 0.055*r* = − 0.130*r* = 0.109Pack-year index*r* = 0.156*r* = − 0.071*r* = 0.029*r* = − 0.084*r* = − 0.098*r* = 0.144\**p* = 0.025; statistical significance for remaining correlation coefficients was not reached*FTND* Fagerström test for nicotine dependence

Correlations between metabolic parameters are presented in Table [6](#Tab6){ref-type="table"}. There was a significant positive correlation between serum levels of [l]{.smallcaps}-arginine, ADMA, and [l]{.smallcaps}-arginine:ADMA ratio. Serum [l]{.smallcaps}-citrulline levels positively correlated with serum levels of ADMA, SDMA, and dimethylamine. There was a significant positive correlation between serum levels of SDMA and ADMA, as well as between serum levels of dimethylamine and SDMA. Although these analyses were conducted on apparently healthy individuals and therefore the individual variability in measured parameters was relatively low, similar correlation patterns were reported in patients with chronic kidney disease \[[@CR37]\]. DMA correlation with SDMA may be result of both metabolites being excreted with urine and reportedly reflect kidney function \[[@CR11], [@CR38]\].Table 6Correlations between metabolic parameters[l]{.smallcaps}-Arginine[l]{.smallcaps}-CitrullineADMASDMADMA[l]{.smallcaps}-Arginine: ADMA[l]{.smallcaps}-Arginine--[l]{.smallcaps}-Citrulline*r* = 0.221--ADMA*r* = 0.308^a^*r* = 0.318^a^--SDMA*r* = 0.145*r* = 0.480^b^*r* = 0.413^b^--DMA*r* = 0.058*r* = 0.302^c^*r* = 0.020*r *= 0.320^a^--[l]{.smallcaps}-Arginine: ADMA*r* = 0.837^c^*r* = 0.117*r* = − 0.199*r* = − 0.033*r* = 0.069--^a^*p* \< 0.01^b^*p* \< 0.001^c^*p* \< 0.05

There was no significant effect of gender on serum levels of metabolic parameters with exception of [l]{.smallcaps}-citrulline. Specifically, males had significantly higher levels of [l]{.smallcaps}-citrulline (26.03 ± 4.88 vs. 22.34 ± 7.12, *p* = 0.019).

Conclusion {#Sec15}
==========

The liquid chromatography Q-TOF hybrid high-resolution mass spectrometry method applies a process of simultaneous extraction and derivatization of the intermediates and derivatives of NO metabolism using the benzoyl chloride as derivatization reagent. The analyte concentrations obtained with our method were within a range reported by others for serum samples using HPLC analysis or LC--MS/MS technique. To minimize matrix impact on quantitative measurements, a stable internal standard, D7-ADMA, was used for the determination of ADMA, SDMA, and [l]{.smallcaps}-citrulline. The use of D7-ADMA allowed us to achieve high accuracy and precision without increasing costs of the analysis. The LC--ESI--QTOF methodology reported here for serum samples is simple, fast, accurate, and precise, and may be useful for the determination of [l]{.smallcaps}-arginine, ADMA, SDMA, [l]{.smallcaps}-citrulline, and DMA in biological samples. Our approach allows for simultaneous assessment of a panel of intermediates and derivatives of NO metabolism and as such is a time- and cost-saving approach. In addition, simultaneous analysis of several compounds reduces the required amount of biological material compared with the several single-compound analyses, making the method more suitable for application in clinical/diagnostic laboratory. Moreover, our LC--ESI--QTOF method allowed for including DMA in a panel of NO-associated metabolites. Simultaneous determination of DMA and citrulline can be of interest as a better surrogate indicator of DDAH activity than citrulline alone due to citrulline being a coproduct of NOS as well as substrate in arginine synthesis \[[@CR39], [@CR40]\]. Owing to its being secreted with urine, DMA accumulation in blood, similar to that of SDMA \[[@CR41]\], may reflect impairment of kidney function. Moreover, little is known about pathophysiological role of DMA. Nonetheless, it has been shown that, in the presence of increased NO concentration, an active carcinogen---dimethylnitrosamine---is formed from DMA \[[@CR42]\].
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*m/z*

:   Mass to charge ratio

MRM

:   Multiple reaction monitoring

NO

:   Nitric oxide

NOS

:   Nitric oxide synthase

OPA

:   Ortho-phthaldialdehyde

QC

:   Quality control samples

SDMA

:   Symmetric dimethylarginine

TFA

:   Trifluoroacetic acid
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